UK Biobank: Consequences for commons and innovation

Farah Huzair and Theo Papaioannou

Science and Public Policy, 2012, vol. 39, issue 4, 500-512

Abstract: Biobanks as collections of population level genetic and health data will be central to the innovation of new drugs and drug targets. The UK Biobank, funded by massive public and charitable investment, was created to store and manage the genetic and health data of over 500,000 people in the UK. The UK Biobank will be available to researchers from both private and public sectors, and is intended to support innovation and serve the public good. We argue that the UK Biobank faces a dilemma in that the knowledge generated is potentially commercialisable and patentable. As knowledge resulting it is transformed into excludable or private goods by scarcity and patenting, it is subject to the tragedies of commons and anti-commons. We question whether the current ethics and governance framework can ensure that benefits will optimally accrue to the public who have funded and contributed samples to the resource. Copyright The Author 2012. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com, Oxford University Press.

Date: 2012
References: Add references at CitEc
Citations:

Downloads: (external link)
http://hdl.handle.net/10.1093/scipol/scs036 (application/pdf)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oup:scippl:v:39:y:2012:i:4:p:500-512

Access Statistics for this article

Science and Public Policy is currently edited by Nicoletta Corrocher, Jeong-Dong Lee, Mireille Matt and Nicholas Vonortas

More articles in Science and Public Policy from Oxford University Press
Bibliographic data for series maintained by Oxford University Press ().